The Effects Of Early Postoperative Hipc Combined With Venous Chemotherapyon The Clinical Efficacy And Immune Function For Gastric Cancer

Objective:To observe the different effects between early postoperativehyperthermic intraperitoneal perfusion chemotherapy combined with venouschemotherapy and conventional intravenous chemotherapy on the patients’ treatment;To compare the effect of two methods of treatment on immune function in patientswith gastric cancer, thus to provide clinical basis for the further treatment and seek formore reasonable and comprehensive program to treat gastric cancer.Methods:Our department has treatedninety-six cases of surgery patients with gastriccancer from October1,2010to September30,2011.They were divided into twogroups according to the random number. The patients in therapeutic group wreaccepted hyperthermic intraperitoneal perfusion chemotherapy with PDD in one ortwo days after the operation. The treatment temperature was maintained between42℃and43℃and the duration was from60to90minutes. The therapeutic groupand control group were all accepted intravenous chemotherapy with the same standardchemotherapeutic regimen after the operation for two weeks. The difference of effectwas compared with statistical analysis(X2text or t test) after two chemotherapycycle.Before and after the treatment, the two groups were respectively abstractedserum samples to exam the subsets of T cells and whether there were changes ofimmune function of two groups before and after the treatment was compared(t test). Results:1.There was no significant effect of early postoperative HIPC on the patient’svital signs (P>0.05); there was no significant difference between two groups inadverse effects (P>0.05); the improvement of life quality of therapeutic group wasbetter than the control group (P<0.05); the local recurrence rate of therapeutic groupwas lower than control group (P<0.05); and there is no significant difference betweentwo groups in distant metastatic rate and survival rate (P<0.05).2.The immune function of two groups was respectively tested before and afterthe treatment then they were compared by t test. The value of CD3+, CD4+,CD4+/CD8+of therapeutic group was higher than those before the treatment and thevalue of CD8+was reduced, with significant difference (P<0.01); the value of CD3+,CD8+, CD4+/CD8+of control group had no obvious changes before and after thetreatment, with no significant difference (P>0.05).Conclusion:1. There is no significant effect in vital signs of the early postoperative patientstreated with HIPC by utilizing high precise perfusion machine. The course oftreatment is safe and feasible.2. The adverse effects of HIPC is little and with no obvious complications, whichcan significantly improve the gastric cancer patient ’s life quality and reduce thepostoperative local recurrence rate.3. Compared with venous chemotherapy, HIPC combined with venouschemotherapy can significantly improve the immune function of patients with gastriccancer.